ATE191145T1 - Hydralazin zur topischen behandlung von glaukom - Google Patents

Hydralazin zur topischen behandlung von glaukom

Info

Publication number
ATE191145T1
ATE191145T1 AT93202327T AT93202327T ATE191145T1 AT E191145 T1 ATE191145 T1 AT E191145T1 AT 93202327 T AT93202327 T AT 93202327T AT 93202327 T AT93202327 T AT 93202327T AT E191145 T1 ATE191145 T1 AT E191145T1
Authority
AT
Austria
Prior art keywords
glaucoma
hydralazine
topical treatment
site
hydrocephalus
Prior art date
Application number
AT93202327T
Other languages
English (en)
Inventor
James A Nathanson
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE191145T1 publication Critical patent/ATE191145T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
AT93202327T 1987-01-23 1988-01-22 Hydralazin zur topischen behandlung von glaukom ATE191145T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US640587A 1987-01-23 1987-01-23

Publications (1)

Publication Number Publication Date
ATE191145T1 true ATE191145T1 (de) 2000-04-15

Family

ID=21720700

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93202327T ATE191145T1 (de) 1987-01-23 1988-01-22 Hydralazin zur topischen behandlung von glaukom

Country Status (6)

Country Link
EP (2) EP0341264A4 (de)
JP (1) JP2845913B2 (de)
AT (1) ATE191145T1 (de)
CA (1) CA1319099C (de)
DE (1) DE3856401D1 (de)
WO (1) WO1988005306A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975428A (en) * 1988-05-31 1990-12-04 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
US5204327A (en) * 1988-11-18 1993-04-20 Ashi Kasei Kogyo Kabushiki Kaisha Treatment of cerebral edema with anp pharmaceutical compositions
US5175161A (en) * 1989-04-06 1992-12-29 Sankyo Company, Limited Occular hypotensive agents
EP0406210B1 (de) * 1989-06-29 1995-09-27 Washington University Ophthalmikum
EP0486621A4 (en) 1989-08-09 1993-03-31 The Children's Medical Center Corporation Nmda oxidizing agents for protecting neurons from injury
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US6071876A (en) * 1991-04-19 2000-06-06 Children's Medical Center Corporation Method of preventing NMDA receptor complex-mediated neuronal damage
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US5602143A (en) * 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
EP0814809B1 (de) * 1994-12-13 2003-08-13 Euroceltique S.A. Arylthioxanthine
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
DE19903087A1 (de) * 1999-01-27 2000-08-10 Forssmann Wolf Georg Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
US6482854B1 (en) 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
GB0107033D0 (en) * 2001-03-21 2001-05-09 Chumas Paul D Method and composition
EP2944648B1 (de) * 2001-03-29 2019-11-13 Bausch Health Ireland Limited Guanylat-Cyclase-Rezeptor-Agonisten zur Behandlung von Organentzündung
ES2475240T3 (es) 2001-06-12 2014-07-10 Janssen Pharmaceutica Nv Derivados de imidazol tetrac�clicos sustituidos novedosos, procesos para su preparación, composiciones farmacéuticas que los comprenden y su uso como medicamento
FR2851247B1 (fr) 2003-02-19 2007-06-29 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de pathologies degeneratives oculaires
EP2998314B1 (de) 2007-06-04 2020-01-22 Bausch Health Ireland Limited Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2373296B1 (de) 2008-12-03 2016-08-03 Synergy Pharmaceuticals Inc. Formulierungen von guanylatcyclase-c-agonisten und anwendungsverfahren
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
EP2990032A1 (de) * 2010-08-03 2016-03-02 G. Pohl-Boskamp GmbH & Co. KG Verwendung von glyceryltrinitrat zur behandlung traumatischer ödeme
WO2012037380A2 (en) 2010-09-15 2012-03-22 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2012219926B2 (en) 2011-02-25 2016-11-17 G. Pohl-Boskamp Gmbh & Co. Kg Stabilized granules containing glyceryl trinitrate
HUE033092T2 (hu) 2012-05-31 2017-11-28 G Pohl-Boskamp Gmbh & Co Kg Arteriogenezis indukálása nitroglicerinnel mint nitrogén-oxid donorral
US9248099B2 (en) 2012-05-31 2016-02-02 Desmoid Aktiengesellschaft Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
CN104768533A (zh) * 2012-06-11 2015-07-08 马库克利尔公司 治疗性制剂和治疗方法
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2878310B1 (de) 2013-11-29 2017-01-11 G. Pohl-Boskamp GmbH & Co. KG Sprühbare wässrige Zusammensetzung mit Nitroglycerin
WO2015152416A1 (ja) * 2014-04-04 2015-10-08 国立大学法人東北大学 眼圧降下剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496544A (en) * 1983-11-10 1985-01-29 Washington University Atrial Peptides
US4508712A (en) * 1984-01-10 1985-04-02 Washington University Atrial peptide
AU4292785A (en) * 1984-04-24 1985-11-15 Salk Institute For Biological Studies, The Atrial peptide analogs
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
US4762851A (en) * 1985-11-29 1988-08-09 Merck & Co., Inc. Pyroglutamic acid esters used as dermal penetration enhancers for drugs
DE3614833A1 (de) * 1986-01-16 1987-07-23 Hoechst Ag Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung

Also Published As

Publication number Publication date
EP0341264A4 (en) 1991-03-20
EP0341264A1 (de) 1989-11-15
DE3856401D1 (de) 2000-05-04
EP0583821B1 (de) 2000-03-29
JPH02502635A (ja) 1990-08-23
EP0583821A1 (de) 1994-02-23
JP2845913B2 (ja) 1999-01-13
CA1319099C (en) 1993-06-15
WO1988005306A1 (en) 1988-07-28

Similar Documents

Publication Publication Date Title
DE3856401D1 (de) Hydralazin zur topischen Behandlung von Glaukom
DE3789053D1 (de) Vorrichtung zur Behandlung von Hypertrophie der Vorsteherdrüse.
ATE88097T1 (de) Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut.
DE69328474T2 (de) Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose
DE3855891T2 (de) Gerät zur Behandlung mittels Zentrifugieren
DE69109560D1 (de) Fungizide Zusammensetzung zur Behandlung von Saatgut.
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE3872012T2 (de) Verfahren fuer die behandlung von abwasser aus photoprozessen mittels konzentration durch verdampfen.
DE3882642D1 (de) Substituierte tetraline, chromane und verwandte verbindungen fuer die behandlung von asthma, arthritis und verwandte krankheiten.
DE69200684T2 (de) Vorrichtung zur thermischen Behandlung von laufenden Garnen.
DE3888056D1 (de) Oxadiazolyl-azabicycloheptane zur Behandlung von seniler Demenz.
AT376355B (de) Mittel zur behandlung gewebeverletzter pflanzen
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE69431199T2 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ATE135220T1 (de) Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
ATE187442T1 (de) Tryptamine zur behandlung von störungen der circadianen rhythmik
ATE116851T1 (de) 5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung in der behandlung neurodegenerativer beschwerden.
PT77020B (de) Mittel zur behandlung von wunden
DE69903931D1 (de) Vorrichtung zur behandlung von wasser
DK320081A (da) Fremgangsmaade til fremstilling af thiazolyl-2-oxamidsyrederivater
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
SU724885A1 (ru) Способ обработки вохдуха
DE68918449T2 (de) Siliziumverbindungen zur behandlung von knochen.
DE69022027T2 (de) 2-Alkyl-3-benzoylbenzofurane zur Behandlung von Herzarrhythmia.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties